baber/WOPTO huggingface dataset:
Patent PT-669340-E (PT)
Inventor: RICHARD LISOWSKY DR
IPC: C07F17/00
Filed: 1994-08-05
Abstract: The prodn. of bridged, stereo-rigid metallocenes of formula (I) Q(CpRa)(Cp'R'a')M(X)n (I) comprises (1) reacting cyclopentadienyl cpds. with Mg cpds.: 2CpRa + (R<3>R<4>)cMg---> (CpRa)2Mg + cR<3>H + cR<4>H, (2) reacting the prods. with cpds. of formula X<1>QX<2>:(CpRa)2Mg + X<1>QX<2> --->(CpRa)2Q + MgX<1>X<2>, (3) reacting the prods. with Mg cpds. as above: (CpRa)2Q + (R<3>R<4>)cMg ---> Q(CpRa)2Mg + cR<3>H + cR<4>H, (4) reacting the prods. with organotin cpds.: Q(CpRa)2Mg + 2R<6>4-kSnX<3>k ---> Q(CpRa)2(SnC<3>k-1R<6>4-k)2 + MgX<3>2, (5) reacting the prods. with transition metal halides: Q(CpRa)2(SnX<3>k-1R<6>4-k)2 + MXm --- Q(CpRa)2MX2 + 3SnX<3>k-1XR<6>4-k, Cp = cyclopentadienyl, indenyl or fluorenyl, R, R' = alkyl, phosphino, amino, alkyl ether or aryl ether gp., with a = 0-4 and a' = 0-4, Cp' = one of the Cp gps. or NR" (with R" = alkyl or aryl with a = 1), Q = single- or multi-membered bridge -(ZR<1>R<2>)b- between Cp and Cp' (with R<1>, R<2> = H, 1-10C alkyl or 6-10C aryl, Z = C, Si or Ge, b = 1, 2 or 3), M = Gp. 3-6 transition metal pref. Zr or Hf, X, X<3> = halo, pref. Cl or Br, n = oxidn. no. of M minus 2, R<3>, R<4> = H or 1-12C alkyl (with c = 0 or 1), X<1>, X<2> = Cl, Br, I or -OSO3R<5> (with R<5> = 1-10C alkyl or 6-10C aryl), R<6> = 2-20C (pref. 4-8C) alkyl or 6-10C aryl, k = 1-4. m = oxidn. no. of M. Also claimed are tin cpds. of formula (II) Q(CpRa)(Cp'R'a')(SnX<3>k-1R<6>4-k)2 (II)
Patent PT-687270-E (PT)
Inventor: CHOREV MICHAEL
IPC: C07K7/06
Filed: 1994-03-04
Abstract: PCT No. PCT/GB94/00416 Sec. 371 Date Jan. 5, 1996 Sec. 102(e) Date Jan. 5, 1996 PCT Filed Mar. 4, 1994 PCT Pub. No. WO94/20529 PCT Pub. Date Sep. 15, 1994The invention relates to biochemically pure oligopeptides having stimulatory activity on osteoblastic and/or fibroblastic cells having a molecular weight between 200 and 2,000. Preferred oligopeptides according to the invention comprise the amino acid sequences Tyr-Gly-Phe-His-Gly (SEQ.ID.No.2) and Gly-Phe-Gly-Gly (SEQ.ID.No.3). The invention further relates to pharmaceutical compositions for the stimulation of formation of osteoblastic or fibroblastic cells, enhanced bone formation in osteogenic pathological conditions, fracture repair, healing of wounds, intraosseous implants and bone supplementation, or other conditions requiring enhanced bone formation cells comprising a therapeutically effective amount of an oligopeptide according to the invention.
Patent PT-671174-E (PT)
Inventor: LOWE LIONEL BARRY
IPC: A23K20/195
Filed: 1995-03-07
Abstract: This invention relates to a formulation for increasing weight of livestock comprising an ionophore, selenium and a veterinary acceptable carrier, diluent, excipient and/or adjuvant. The invention also relates to a method of increasing liveweight gain in livestock comprising, administering to said livestock an effective amount of a formulation of the invention. The invention further relates to a method of increasing selenium absorption in livestock comprising, administering to said livestock an effective amount of an ionophore.
Patent PT-772437-E (PT)
Inventor: CARRANO RICHARD A
IPC: C12N15/87
Filed: 1995-03-30
Abstract: Methods of introducing genetic material into cells of an individual and compositions and kits for practising the same are disclosed. The methods comprise the steps of contacting cells of an individual with a genetic vaccine facilitator and administering to the cells a nucleic acid molecule that is free of retroviral particles. The nucleic acid molecule comprises a nucleotide sequence that encodes a protein that comprises at least one epitope that is identical or substantially similar to an epitope of a pathogen antigen or antigen associated with a hyperproliferative or autoimmune disease, a protein otherwise missing from the individual due to a missing, non-functional or partially functioning gene, or a protein that produces a therapeutic effect on an individual. Methods of prophylactically and therapeutically immunizing an individual against HIV are disclosed. Pharmaceutical compositions and kits for practising methods of the present invention are disclosed.
Patent PT-791006-E (PT)
Inventor: ELLINGBOE JOHN WATSON
IPC: A61K31/70
Filed: 1995-11-03
Abstract: This invention relates to the use of polyanionic benzylglycosides as smooth muscle cell proliferation inhibitors and as therapeutic compositions for treating diseases and conditions which are characterized by excessive smooth muscle proliferation, such as restenosis. The compounds of this invention are those of formula I    <IMAGE>  I    <IMAGE>   wherein each of R1, R2, R3, and R4 are, independently, H, SO3M, or   <IMAGE>   and each oligosaccharide group contains 1 to 3 sugar groups; M is lithium, sodium, potassium, or ammonium; n is 1 or 2; X is a halogen, lower alkyl having 1 to 6 carbon atoms, or lower alkoxy having 1 to 6 carbon atoms; Y is carbonyl or sulfonyl; Z is alkyl from 1 to 12 carbon atoms,   <IMAGE>    <IMAGE>    <IMAGE>   and X is as defined above; or a pharmaceutically acceptable salt thereof.
Patent PT-819290-E (PT)
Inventor: OTT REINHOLD
IPC: G08B13/14
Filed: 1996-04-04
Abstract: A device is proposed for securing articles from theft. The device is simple to manufacture, while being remarkably secure and universally useable. It comprises a first securing part for attachment to an object, a second securing part for attachment to the article and a cable which connects the two securing parts. At least one of the securing parts includes a sensor element for monitoring that the securing part is properly attached to the object or article, and at least one securing part includes monitoring means connected to the sensor element and so designed as to ensure that an alarm is set off if one attachment monitored by the sensor element is disrupted.
Patent PT-836770-E (PT)
Inventor: LOMP GARY
IPC: H04B17/00
Filed: 1996-06-27
Abstract: A multiple access, spread-spectrum communication system processes a plurality of information signals received by a Radio Carrier Station (RCS) over telecommunication lines for simultaneous transmission over a radio frequency (RF) channel as a code-division-multiplexed (CDM) signal to a group of Subscriber Units (SUs). The RCS receives a call request signal that corresponds to a telecommunication line information signal, and a user identification signal that identifies a user to receive the call. The RCS includes a plurality of Code Division Multiple Access (CDMA) modems, one of which provides a global pilot code signal. The modems provide message code signals synchronized to the global pilot signal. Each modem combines an information signal with a message code signal to provide a CDM processed signal. The RCS includes a system channel controller coupled to receive a remote call. An RF transmitter is connected to all of the modems to combine the CDM processed signals with the global pilot code signal to generate a CDM signal. The RF transmitter also modulates a carrier signal with the CDM signal and transmits the modulated carrier signal through an RF communication channel to the SUs. Each SU includes a CDMA modem which is also synchronized to the global pilot signal. The CDMA modem despreads the CDM signal and provides a despread information signal to the user. The system includes a closed loop power control system for maintaining a minimum system transmit power level for the RCS and the SUs, and system capacity management for maintaining a maximum number of active SUs for improved system performance. <IMAGE>
Patent PT-776758-E (PT)
Inventor: RUPPEL REMY
IPC: B31F1/07
Filed: 1993-11-22
Abstract: The cellulose fibre tissue product (1), for use as handkerchief or napkin, is made by at least two ply cellulose pads (1a,1b). These are cut to required form and joined together along a peripheral border (3), by adhesive. The join presents a minimal resistance to delamination of 1 g/cm., the border area being less than 50% of total tissue surface area. The adhesive may be on the border of each ply, distributed as discontinuous spots (5). Alternatively, the borders may also be embossed, like waffles. The several ply may have differing composition.
Patent PT-927195-E (PT)
Inventor: LINNAU YENDRA
IPC: C07K14/76
Filed: 1997-09-10
Abstract: There is disclosed a method of preparing a plasma-protein-containing medicament from citrated plasma or from a citrate-containing plasma fraction, the medicament being substantially free from undesired metals, which method comprises the following steps: exchanging the citrate and optionally citrate-bound metals in a plasma-protein-containing solution for a water-soluble mono- or dicarboxylate or for an organic mono- or dicarboxylic acid under non-precipitating conditions, recovering the plasma protein or the plasma proteins, and finishing the medicament.
Patent PT-942876-E (PT)
Inventor: FILECCIA SALVATORE
IPC: B65D71/00
Filed: 1997-11-24
Abstract: This invention concerns a process for stacking enveloping packaging units which can be filled with non-self-supporting containers and are composed of trays and hooded lids, with which the problem of increasing display efficiency is solved. In particular, this is done in such a way that the greatest number of packaging units are on display ready for sale in the store without the entire stack collapsing or the containers, which are not self-supporting, being crushed. This is achieved in that the hooded lids (4) of the enveloping packaging units (1) (in the ready for sale position) are removed and vertical carton blanks (6) designed as support elements (6) are inserted between the non-self-supporting containers (2).
Patent PT-1021534-E (PT)
Title: Hepatitis c receptor protein cd81
Inventor: ABRIGNANI SERGIO
IPC: A61P31/20
Filed: 1998-10-06
Abstract: The present invention relates to the use of CD81 protein and polynucleic acid in the therapy and diagnosis of hepatitis C and pharmaceutical compositions, animal models and diagnostic kits for such purposes.
Patent PT-1144006-E (PT)
Title: Ccr5 antibody pa14
Inventor: OLSON WILLIAM C
IPC: A61K38/00
Filed: 1999-12-16
Abstract: A nucleic acid encoding a polypeptide which is a chain of an anti-CCR5 chemokine receptor monoclonal antibody or a fragment thereof, wherein the antibody or fragment thereof binds to the same epitope as that to which monoclonal antibody PA14 binds, PA14 being the monoclonal antibody produced by a hybridoma cell line deposited under ATCC Accession No. HB-12610 and designated PA14.
Patent SG-60893-G (SG)
Title: Improvements in electro optical switch architectures
IPC: H04B10/291
Filed: 1993-05-07
Abstract: Optical switch networks and the design rules for creating them are disclosed. The networks comprise a plurality of input and output stages of optical switch elements. Each input optical switch stage is comprised of a plurality of 1 by 2 optical switch elements and each output stage is comprised of a plurality of 2 by 1 optical switch elements. Using these stages, optical switch networks are constructed where switch elements are interconnected by optical waveguides diffused in a substrate. Further, the connections between adjacent stages include optical waveguide crossovers (crossthroughs).
Patent IE-840106-L (IE)
Title: Vascular prosthesis from a knitted tube
IPC: A61F2/06
Filed: 1984-01-18
Abstract: A vascular prosthesis to be used as a graft for replacing a portion of a blood vessel is in the form of a knitted tubular structure (1) the wall (2,3) of which comprises several strata (4,5,6) of which each stratum has characteristics different from those of at least one of the other strata. The prosthesis provides specific characteristics by determining individually the characteristics of each stratum (4,5,6).
[EP0117072A1]
Patent IE-36125-L (IE)
Title: Diphenylamine derivatives
IPC: C09B51/00
Filed: 1972-02-29
Abstract: 1383306 Diphenylamines IMPERIAL CHEMICAL INDUSTRIES Ltd 21 Feb 1972 [19 March 1971] 7292/71 Heading C2C [Also in Division A5] Diphenylamines of formula wherein R<SP>1</SP> to R<SP>10</SP> represent hydrogen or halogen atoms or cyano, nitro, perhalocarbyl, carboxy, sulphonamido, hydrocarbyloxy, hydrocarbylthio or hydrocarbylamino groups, provided that (a) no more than 3 of R<SP>1</SP> to R<SP>10</SP> are H atoms, (b) at least 4 but not more than 9 of R<SP>1</SP> to R<SP>10</SP> are halogen atoms, and at least one of R<SP>1</SP> to R<SP>10</SP> represents a substituent other than H or halogen, except that R<SP>1</SP> cannot be nitro or amino where R<SP>2</SP> and R<SP>4</SP> is fluoro, bromo or methoxy and (c) at least 7 of R<SP>1</SP> to R<SP>10</SP> must be halogen atoms when a nitro group and a trifluoromethyl group are both present unless a group other than halogen, trifluoromethyl or nitro is also present and (d) no more than three of R<SP>1</SP> to R<SP>10</SP> are nitro groups. The compounds may be prepared by treating a compound of formula with a base, e.g. sodium hydride, and then reacting the treated compound thus produced with a compound of formula wherein R<SP>1</SP> to R<SP>10</SP> have the meanings hereinbefore defined. The process may be carried out in a diluent or solvent, e.g. D.M.F.
[GB1383306A]
Patent IE-890673-L (IE)
Title: Pharmaceutical compositions having antineoplastic activity
IPC: A61K31/095
Filed: 1989-03-02
Abstract: Compositions containing as antineoplastic active principle only dialkyl diselenides show a very promising activity not withstanding a remarkably lower toxicity in comparison with that of known combinations of the same dial kyldiselenides with other active principles.
Patent IE-34335-L (IE)
Title: Profiled polymer film web.
IPC: B29C59/04
Filed: 1970-06-24
Abstract: 1306214 Profiled films SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ NV 26 May 1970 [26 June 1969] 32365/69 Headings B5A and B5B [Also in Division B6] In a process for forming a profiled film web of a molecularly-orientable synthetic organic polymer a moving sheet-like mass 2 of the polymer is brought into contact, at a temperature above its crystalline melting point, with a profiling element (e.g. a ridged roller 3) having a ridged surface adapted to form a plurality of closely-spaced longitudinal grooves on one surface of the sheet, the profiled film web 2<SP>1</SP> so formed being drawn away from the profiling element at a speed faster than the sheet-like mass is supplied thereto so as to effect a melt draw-down of the web prior to the web being cooled to a temperature below its crystalline melting point. As illustrated the profiling element preferably includes an unridged backup roller 4 and the cooling and draw-down of the profiled web is achieved by a movable element which is internally water-cooled and driven at a speed faster than the surface speed of the profiling element. The chilled profiled film web may be converted into filaments or fibres by longitudinally stretching the film at a stretch ratio and under conditions such that it fibrillates under conventional fibrillation treatments. In an example a sheet of polypropylene is extruded, profiled, cooled and stretched at 145‹ C. a ratio of 8 : 1 between two sets of Godet rollers. The filaments so produced had an average denier of 22.
[GB1306214A]
Patent IE-45034-L (IE)
Title: Orthopaedic fracture fixing apparatus
IPC: A61B17/66
Filed: 1977-04-26
Abstract: This invention concerns variably connectable orthopaedic fracture fixing apparatus of a kind comprising at least one elongate member, at least two universal joint assemblies for coupling said member and associated bone pins, and an adjustment assembly for adjusting the spacing between said joint assemblies when connected with said member. In the present case the joint assemblies are each of ball joint form in which a ball is clamped by a wedge action between two sockets. Also, the adjustment assemblies are not necessarily integrated with a fracture fixing network constructed with the apparatus, but are separable therefrom. In addition, the joint assemblies can receive bone pins in a variety of closely spaced positions to minimize any need to stress the pins.
[US4135505A]
Patent IE-44369-L (IE)
Title: Triazine preparation
IPC: C07D251/46
Filed: 1976-05-05
Abstract: Prepn. of triazine herbicides of formula (I): (where R' is 2-8C alkyl, 5-8C cycloalkyl, norbornyl, methylcyclohexyl, methylcyclopentyl, phenyl or chlorophenyl; R3 is Me; R4 is 1-4C alkyl) is by (a) treatingcyanamide with an alkyl chloroformate RO2C.Cl to give an alkoxycarbonylcyanamide; (b) treating the prod. with an alkylating agent CH3.Z to give an N-Alkoxy-carbonyl-N-methylcyanamide; (c) treating this cpd. with an amine salt of formula R3R4.NH2 +n.Yn-5 (where n is 1 when Y is Cl-; n is 2 when Y is SO4--) to give a cpd. of formula RO2CN(CH3)C(=NH2)NR3R4 + Yn-; (d) treating this cpd. with an alkali metal hydroxide to give a cpd. of formula: RO2CN(CH3)C(=NH)NR3R4; (e) removing unreacted amine R3R4NH; (f) treating the prod. from (d) with an isocyanate R1.NCO to give a cpd. RO2CN(CH3)C(=NCONHR') NR3R4; (g) treating the prod. with a base M1.OR5 to cyclise it and give (I). (where Z is Br, I or -O3S.OMe; M' is an alkali metal; R is 2-3 C alkyl, R5 is 1-4C alkyl). Process gives increased yields compared with the 5-s stage process of US 3850924, esp. when R is Et. In an example, 1a-methyl-4-cyclohexyl-6-dimethylamino-s-triazine-2, 4(1H,3H)dione was prepd.
[FR2310349A1]
Patent FI-830182-L (FI)
Inventor: SHENOI KISHAN
IPC: H03M3/00
Filed: 1983-01-20
Abstract: A Delta-Sigma modulator for one-bit analog to digital conversion of a signal (U(t)), such as a telephone voice channel signal to digital form is disclosed. The voice signal is sampled (1, 3, C<sub>1</sub>) at a rate high compared to the highest voice channel frequency component. Sampled instantaneous signal values are integrated (4, C<sub>3</sub>), re-sampled (10, 12, C<sub>4</sub>) and again integrated (17, C<sub>6</sub>) to reduce encoding noise. Finally, a bi-level sense identifying circuit (19) links the second integrator output to a D type flip-flop (20) providing the one-bit encoder output (b(n)).The sampling and integrator control is effected by switching in a capacitor charge shifting arrangement under clock control and feedback is applied as a capacitor switching program modification (301, 302).
Patent FI-844929-L (FI)
Inventor: LERCH ULRICH
IPC: C07D209/52
Filed: 1984-12-13
Abstract: The invention relates to a process for resolving racemic mixtures of bicyclic imino- alpha -carboxylic acid esters into the components of the formula Ia and Ib   <IMAGE>   in which R1 stands for an aliphatic, cycloaliphatic, aromatic or araliphatic radical, A denotes hydrogen and B and C together form a carbon chain or C denotes hydrogen and A and B together form a carbon chain, by crystallizing diastereoisomeric salts, which comprises preparing the salts of the racemic esters with optically active O,O-diacyltartaric acids in a suitable solvent in which only one of the two diastereoisomeric salts crystallizes in optically pure form, if desired purifying the diastereoisomeric salt by recrystallization, reprecipitation or trituration, and finally adding basec to the salt to cleave it into the pure enantiomer of the formula Ia or Ib. The invention also relates to diastereoisomeric salts of an ester of the formula Ia or Ib and a diacyltartaric acid.
Patent FI-851231-L (FI)
Inventor: KOTHS KRISTON EDWARD
IPC: C07K14/55
Filed: 1985-03-27
Abstract: A process for recovering microbially produced IL-2 in a highly pure form from the cellular material of the microorganism that produced it comprising: disrupting the cell membranes of the microorganisms; extracting the disruptate with a chaotropic agent, such as urea, that selectively extracts microbial proteins from the cellular material; solubilizing the IL-2 in the solid phase of the extraction mixture with an aqueous solution of a solubilizing agent, such as SDS, containing a reducing agent; and separating the IL-2 from the resulting solution by an optional extraction with 2-butanol or 2-methyl-2-butanol followed by gel filtration chromatography, oxidizing the IL-2 and purifying the oxidized IL-2 by RP-HPLC.
Patent IE-801081-L (IE)
Title: Bromhexin, benzoxazinone.
IPC: C07D265/18
Filed: 1980-05-23
Abstract: N-(2-amino-3,5-dibromobenzyl)- N-methyl-cyclohexylamine, the hydrochloride of which has the formula <IMAGE> is prepared by brominating 1,4- dihydro-2H-3,1-benzoxazin-2-one with free bromine to form the hitherto unknown intermediate 6,8-dibromo- 1,4-dihydro-2H-3,1-benzoxazin-2- one, and reacting this with N-methyl- cyclohexylamine to bromhexin. Preferably, the reaction takes place by heating in N-monomethylformamide to the boiling point of the latter.
[GB2053900A]
Patent IE-821225-L (IE)
Title: Preparation of 1-(3-halo-2-pyridinyl) piperazines
IPC: C07D213/74
Filed: 1982-05-21
Abstract: 1-(3-Halo-2-pyridinyl)piperazine and its acid addition salts are selective  alpha 2-adrenergic receptor antagonists and thereby useful as antidepressant agents and for treating sedation caused by antihypertensive therapy.
Patent IE-34755-L (IE)
Title: Preparing olefin oxide.
IPC: C25B3/23
Filed: 1970-11-23
Abstract: 1308350 Olefin oxides INTEROXO AG 23 Nov 1970 [24 Nov 1969 30 Sept 1970] 55695/70 Heading C2C [Also in Division C7] Olefin oxides are prepared by electrolysing an aqueous solution containing acetate ions, mixing the anolyte so obtained with an olefin, and separating olefin oxide from the resulting effluent. The acetate is preferably one or more acetates of Cu, Co, Th, Ni, Ag, or Li, optionally mixed with acetic acid, and the solution preferably contains a complexing agent, e.g. a nitrogen containing heterocyclic compound such as 1,3,4, triazole, imidazole, pyrazole or a pyridine; the solution may contain 0À5 wt. per cent to just below saturation of acetate ; the preferred olefin is propylene. The olefin is either introduced directly into the cell near the anode, e.g. through a glass frit to cause small bubbles, or mixed with the anolyte in a separate reactor, the anolyte preferably being continuously circulated. Separation of the olefin oxide from unconverted olefin is by refrigeration. The cell used is conventional, with a diaphragm or ion-exchange membrane; the anode may be of Pt, Ru, oxidized Ru, platinized or Ru-coated Ti; oxidized Ru-coated Ti, or lead oxide-coated Ti, and is porous if olefin is fed direct to the cell; the cathode may be of stainless steel or Ni, and the electrolyte may be continuously circulated to ensure uniform temperature. Room temperature may be used, and a current density of 100-500 A/ft<SP>2</SP>. and atmospheric pressure; however other pressures may be used and where anolyte-olefin contact takes place outside the cell, the reaction vessel and cell may be at different temperature and pressure.
[GB1308350A]
Patent IE-821816-L (IE)
Title: Polymerisation of alpha olefins
IPC: C08F4/64
Filed: 1982-07-28
Abstract: A novel process is disclosed for polymerizing and copolymerizing alpha olefins (ethylene included) also in the presence of conjugated diolephins, and more particularly for copolymerizing ethylene with 1,3-butadiene, based on the use of a plural-component catalyst system, one of said components being a novel complex which contains titanium and magnesium. The process gives, in yields higher than 200,000 grams of polymer per g of elemental Ti, ethylene-butadiene copolymers having a distribution of monomeric units characterized by a particular novel 13C-NMR spectrum, a high apparent specific gravity and such a grit size as to impart flowability to the dry product, and a distribution in the presence of sulphur and accelerators such as to acquire a gel content (fraction insoluble in boiling xylenes) over 50%.
[US4446289A]